59.5 F
New York
Thursday, November 26, 2020

AstraZeneca’s [NASDAQ: AZN] Brazilian Volunteer In COVID-19 Vaccine Trial Reportedly Dead

Must read

Verizon [NYSE: VZ] Announced to acquire Tracfone for $6.25 billion.

Verizon Communication Inc. declared that it penned down a deal with America Movil to purchase Tracfone for $6.25B. The companies came to terms...

ViacomCBS [NASDAQ: VIAC] Agreed To Sell Simon And Schuster For $2.175 Billion In Cash

ViacomCBS Inc. declared that it entered into an agreement with Penguin Random House LCC to sell Simon and Schuster. It will be sold...

IBM [NYSE: IBM] Plans To Cut Down 20% Of Its Workforce

International business machines Corp. declared that the company is preparing to cut down 10,000 jobs in Europe which makes it’s 20% of the...

Ford [NYSE: F ] Booked Ultra-Cold Freezers To Ensure Autoworkers Access To The Covid-19 Vaccine

Ford Motors Co. revealed recently that to stock Pfizer Inc Covid-19 vaccine securely, it has requested 12 of the ultra-cold freezer. The automaker...

Brazilian Volunteer in the coronavirus vaccine trial of AstraZeneca [NASDAQ: AZN] and Oxford University has died. Authorities of Brazil disclosed that the testing of the vaccine continues despite the death of the participant.

Brazilian Health Authority has confirmed the news and revealed that it had just got the information from an investigation into the death.

The volunteer identity hasn’t disclosed yet and it is not clear whether the person is died because of the vaccine or due to an unrelated pre-existing condition.

Share of AstraZeneca traded down 0.53% at $51.92 during the trading session of Wednesday. It had a trading volume of 6.2 million as compared to the average volume of 4.64 million.

In the past 52-weeks of trading, this company’s stock has changed between the 52-weeks low range of $36.15 and a high range of $64.94. It has moved up 43.61% from its 52-weeks low and moved down -20.06% from its 52-weeks high.

Looking at its liquidity, it has a current ratio of 0.80. AZN market capitalization has remained high, hitting $136.45 billion at the time of writing.

The Federal University of São Paulo confirmed the news that the volunteer was Brazilian. The Federal University of São Paulo is helping the coordinate Phase III trial in Brazil. Oxford representative also disclosed that they are no safety concerns regarding the usage of the vaccine candidate.

More articles

Latest article

Transdigm [NYSE: TDG] Enters Into An Agreement To Buy Cobham Aero Connectivity

Transdigm group incorporation , the global aircraft component manufacturer and provider declared the acquisition of Cobham Aero Connectivity, the top supplier of antennas and...

LCI Industries’ [NYSE: LCII] Subsidiary Lippert Components Acquires Challenger Door

LCI Industries has revealed that its unit Lippert Components has completed the acquisition of Challenger Door, Inc. This acquisition will provide the opportunity...

Blackstone Group [NYSE: BX] Finalizes Recapitalization Of BioMed Realty

The Blackstone Group Inc. has disclosed today that Blackstone Real Estate Partners VIII L.P.  has executed the deal related to BioMed Realty. The...

Pfizer-BioNTech’s COVID19 Vaccine Candidate Acheive 95% Success

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have disclosed Wednesday that their COVID-19 vaccine candidate, BNT162b2, has shown a 95% efficacy rate...

Scienjoy [NASDAQ: SJ] Inks Agreement With China Mobile

Scienjoy Holdings Corporation has revealed today that it has inked a cooperative agreement with China Mobile on November 1, 2020. The company disclosed...

Amazon.com [NASDAQ: AMZN] Launch Amazon Pharmacy

Amazon.com, Inc. has disclosed today the launch of two new pharmacy offerings. The e-commerce giant took this initiative for the convenience of its...

Why Alterity [NASDAQ: ATHE] Stock Surging Today?

Shares of Alterity Therapeutics Limited jumped higher on Monday's session with heavy volume. The company declared that it has got the new patent...

Here’s Why Cassava Sciences [NASDAQ: SAVA] Plunged On Friday?

Cassava Sciences Inc. shares plummeted 25.13% during the trading session of Friday. The biotechnology company has announced Friday the pricing of its previously...